Pfizer–BioNTech, Moderna Poised to Make Billions on COVID-19 Booster Shots

Vials of Pfizer–BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021. Dado Ruvic/Illustration/Reuters

The Pfizer–BioNTech alliance and Moderna might reap billions from COVID-19 booster shots in the coming years, in what analysts and investors say could be a market comparable to the $6 billion in annual sales for flu vaccines.

Pfizer, its German partner BioNTech, and Moderna have together locked in more than $60 billion in sales of their respective COVID-19 vaccines through 2022, with the agreements covering initial doses and booster shots, according to Reuters.